344 related articles for article (PubMed ID: 16509421)
1. [Type 2 diabetes mellitus and cardiovascular diseases: evaluation, treatment and prevention strategies].
Mosseri MM; Fisman EZ; Tenenbaum A
Harefuah; 2006 Feb; 145(2):141-6, 164. PubMed ID: 16509421
[TBL] [Abstract][Full Text] [Related]
2. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
Ragucci E; Zonszein J; Frishman WH
Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
[TBL] [Abstract][Full Text] [Related]
4. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
Schneider CA
Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
[TBL] [Abstract][Full Text] [Related]
5. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
Dussol B; Berland Y
Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
[TBL] [Abstract][Full Text] [Related]
6. Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors.
Spellman CW
J Am Osteopath Assoc; 2009 May; 109(5 Suppl):S8-S13. PubMed ID: 19451256
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
8. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance.
Mazzone T
Am J Cardiol; 2004 Jun; 93(11A):27C-31C. PubMed ID: 15178514
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
Rosenberg DE; Jabbour SA; Goldstein BJ
Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
Viberti G
J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
[TBL] [Abstract][Full Text] [Related]
12. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
[TBL] [Abstract][Full Text] [Related]
13. Type 2 diabetes mellitus: prevention of macrovascular complications.
Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of cardiovascular disease in people with dysglycemia.
Bianchi C; Miccoli R; Penno G; Del Prato S
Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
[TBL] [Abstract][Full Text] [Related]
15. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
16. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
Christiansen AL; Madsbad S
Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
[TBL] [Abstract][Full Text] [Related]
17. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
Leschke M
Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease.
Tkác T
Acta Diabetol; 2003 Dec; 40 Suppl 2():S338-42. PubMed ID: 14704865
[TBL] [Abstract][Full Text] [Related]
20. An algorithm for the treatment of type 2 diabetes in Latin America.
Chacra AR; Davidson JA; Diaz J; Escalante-Pulido M; Litwak LE; Mestman JH; More L; Violante RM
Diabetes Obes Metab; 2005 Mar; 7(2):148-60. PubMed ID: 15715888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
